The use of antiepileptic drugs (AEDs) is one of the most frequent causes of adverse reactions secondary to drugs, with variable severity and even death in 35% of cases. Genetic variants are considered a possible causal actor of hypersensitivity reactions, therefore genotyping of the HLA-A and B alleles has proven to be a cost-effective tool in the choice of management in patients with epilepsy. Objective: To determine the most frequent variant of HLA-A and B in patients with epilepsy who present an adverse skin reaction to antiepileptic drugs. Materials and methods: Ambispective case-control study. Convenience sampling, considering the diagnosis of epilepsy for cases and controls, and the diagnosis of adverse reaction to antiepileptic drugs for cases. HLA-A and B haplotypes will be typed from venous blood samples at Yunis Turbay y Cia SAS Medical Services laboratory, in order to compare the results of patients with and without adverse reaction to antiepileptic drugs. Expected results: Finding differences in the HLA-A and B typing of patients with epilepsy treated with AEDs who present cutaneous adverse reactions compared to those with the same diagnosis and treatment that do not present them.